ArticleAlcohol, clinical & experimental research2026
Pharmacological Inhibition of HDAC6 Transiently Reduces Voluntary Ethanol Consumption in Male Mice.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHistone deacetylase 6 (HDAC6) inhibition can alleviate depression- and anxiety-like behaviors. Accordingly, HDAC6 may be a promising target to mitigate negative reinforcement in alcohol use disorder (AUD). We previously reported reduced α-tubulin acetylation in mice withdrawn from chronic intermittent ethanol (CIE) vapor inhalation, suggesting potential HDAC6 hyperactivity in this mouse model of AUD. The present study aimed to probe the behavioral significance of this acetylation deficit by testing whether HDAC6 inhibition can reverse ethanol drinking escalation in CIE-exposed mice.
methodsMale C57BL/6J mice were subjected to limited-access ethanol drinking sessions (two-bottle choice, 2BC) combined with CIE to escalate voluntary ethanol intake relative to air-exposed counterparts (Air). Ethanol and saccharin intake during 2BC was measured after acute and subchronic administration of bavarostat, a brain-penetrant HDAC6 inhibitor. Acetyl-lysine and acetyl-α-tubulin levels were quantified via immunoblotting.
resultsAcute administration of bavarostat at 100 mg/kg, but not lower doses, significantly reduced ethanol intake in both Air and CIE mice. Ethanol intake during subchronic administration of 100 mg/kg bavarostat was reduced on the first day in both Air and CIE mice compared to vehicle-treated counterparts, but this effect was lost on subsequent days. CIE mice also consumed more saccharin than Air controls. Bavarostat did not impact saccharin intake in either group. When saccharin was offered along with ethanol, CIE mice consumed significantly more ethanol and less saccharin than Air counterparts, indicating intact taste discrimination. Bavarostat administered prior to brain collection significantly increased acetyl-lysine and acetyl-α-tubulin levels in the frontal cortex, confirming reduced HDAC6 activity. These levels did not differ between Air and CIE mice.
conclusionsSystemic administration of bavarostat reduces voluntary ethanol drinking in mice. This effect is dose-dependent, selective for ethanol, independent of ethanol dependence, and transient. These findings support HDAC6 as a viable target to acutely reduce the drive to consume ethanol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.